deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03259074

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (SURPASS)

A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

Sponsor: Novartis Pharmaceuticals

Conditions Ankylosing Spondylitis
Interventions AIN457 150 mg GP2017 (adalimumab biosimilar) Placebo
Updated 26 times since 2017 Last updated: Aug 16, 2023 Started: Nov 30, 2017 Primary completion: Nov 12, 2021 Completion: Nov 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ankylosing Spondylitis and is currently completed. Novartis Pharmaceuticals leads this study, which shows 26 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2023 — Sep 2023 [monthly]

    Completed PHASE3

▶ Show 21 earlier versions

  1. Sep 2022 — Apr 2023 [monthly]

    Completed PHASE3

  2. Feb 2022 — Sep 2022 [monthly]

    Completed PHASE3

  3. Jan 2022 — Feb 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  12. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  13. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  14. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  15. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  16. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  17. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  18. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  19. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  20. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  21. Sep 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Almada, Portugal , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Athens, Greece , Bad Doberan, Germany , Badalona, Spain , Barcelona, Spain , Barnaul, Russia and 135 more locations